Madrigal Pharmaceuticals develops treatments for MASH, a serious liver disease, and sells its approved medicine Rezdiffra. MDGL reports earnings on Tue, Nov 3, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in MDGL, 100% of them bullish and 0% bearish. In the past 30 days there were 1 dark pool print.
Prices, price targets and earnings estimates for MDGL are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MDGL is in one of them and how their past MDGL trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals is a biopharmaceutical company based in West Conshohocken, Pennsylvania. It focuses on treatments for MASH, a serious liver disease that can lead to cirrhosis, liver failure and liver cancer. Its main product, Rezdiffra, is an oral medicine taken once a day for adults with moderate to advanced liver scarring who do not have cirrhosis. The company sells Rezdiffra to patients and healthcare providers in the United States and Germany, and it is developing other candidates for the disease.
